NCT07441694 2026-03-19
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
Clinical Trials
59 trialsNCT02386800 2026-03-16
CINC424A2X01B Rollover Protocol
Novartis
Phase 4 Active not recruiting
NCT07469891 2026-03-13
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Phase 1 Not yet recruiting
NCT06985147 2026-03-04
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Disc Medicine, Inc
Phase 2 Recruiting
NCT07232290 2026-03-04
Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 2 Recruiting
NCT06351631 2026-02-20
MK-3543-017
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06093672 2026-01-27
GIV-IN-PV
Italfarmaco
Phase 3 Recruiting
NCT05143957 2026-01-16
A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
Ionis Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT05499013 2025-12-19
SLN
Silence Therapeutics plc
Phase 1/2 Active not recruiting
NCT04182100 2025-09-15
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
PharmaEssentia Japan K.K.
Phase 2 Completed
NCT04629508 2025-09-02
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Incyte Corporation
Phase 2 Completed
NCT06378437 2025-08-19
A Study of GLB-001 in Patients With Myeloid Malignancies
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05481151 2025-08-13
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
PharmaEssentia
Phase 3 Active not recruiting
NCT04057040 2025-08-07
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
Protagonist Therapeutics, Inc.
Phase 2 Completed
NCT05210790 2025-08-07
VERIFY
Protagonist Therapeutics, Inc.
Phase 3 Active not recruiting
NCT06033586 2025-08-06
THRIVE
Protagonist Therapeutics, Inc.
Phase 3 Active not recruiting
NCT05485948 2025-08-03
A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU
PharmaEssentia
Phase 2 Active not recruiting
NCT06290765 2025-07-31
PV
PharmaEssentia
Phase 4 Not yet recruiting
NCT05558696 2025-07-29
MK-3543-004
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Phase 2 Completed
NCT07012109 2025-06-10
Study of BEBT-507 Injection in Subjects With Polycythemia Vera (PV)
BeBetter Med Inc
Phase 1 Not yet recruiting
NCT06752746 2025-05-11
A Study of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of 9MW3011 in Patients With Polycythemia Vera
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1 Recruiting
NCT01761968 2025-04-30
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
Italfarmaco
Phase 2 Active not recruiting
NCT04041050 2025-02-14
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie
Phase 1 Active not recruiting
NCT04655092 2024-11-08
Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients
PharmaEssentia Japan K.K.
Phase 3 Recruiting
NCT06002490 2024-11-08
A Study to Evaluate P1101 in Japanese PV Patients
PharmaEssentia Japan K.K.
Phase 3 Completed
NCT04637009 2024-08-02
A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
Astex Pharmaceuticals, Inc.
Phase 1 Terminated
NCT04767802 2024-03-18
PACIFIC
Protagonist Therapeutics, Inc.
Phase 2 Completed
NCT05074550 2023-07-24
Safety Evaluation Study for Patients With Polycythemia Vera
Perseus Proteomics Inc.
Phase 1 Unknown
NCT04896112 2023-06-18
A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia
Lynk Pharmaceuticals Co., Ltd
Phase 1 Withdrawn
NCT04354727 2022-07-12
A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Ascentage Pharma Group Inc.
Phase 1/2 Withdrawn
NCT01981850 2022-01-05
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
Hoffmann-La Roche
Phase 2 Completed
NCT03287245 2021-12-08
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera
Hoffmann-La Roche
Phase 2 Terminated
NCT02055781 2021-11-18
PAC326
CTI BioPharma
Phase 3 Terminated
NCT02038036 2021-07-20
RESPONSE-2
Novartis
Phase 3 Completed
NCT02218047 2021-06-01
CONTI-PV
AOP Orphan Pharmaceuticals AG
Phase 3 Completed
NCT04283526 2021-03-04
Study of Select Combinations in Adults With Myelofibrosis
Novartis
Phase 1 Withdrawn
NCT01773187 2020-09-29
Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
CTI BioPharma
Phase 3 Terminated
NCT03121599 2020-08-11
18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms
Hamad Medical Corporation
Phase NA Terminated
NCT03669965 2020-07-31
KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera
Kartos Therapeutics, Inc.
Phase 2 Unknown
NCT01998828 2020-04-20
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
Phase 2 Terminated
NCT01787552 2020-04-15
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
Novartis
Phase 1/2 Completed
NCT00606307 2019-12-03
Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
Italfarmaco
Phase 2 Completed
NCT00928707 2019-10-31
PV
Italfarmaco
Phase 2 Completed
NCT01901432 2019-07-30
A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera
Italfarmaco
Phase 1/2 Completed
NCT02292446 2019-07-18
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.
Novartis
Phase 3 Completed
NCT01243944 2019-03-06
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Incyte Corporation
Phase 3 Completed
NCT01134120 2018-04-17
A Study in Myeloproliferative Disorders
Eli Lilly and Company
Phase 1 Completed
NCT00509899 2018-03-12
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Incyte Corporation
Phase 1/2 Completed
NCT01193699 2018-01-30
PEGINVERA
AOP Orphan Pharmaceuticals AG
Phase 1/2 Completed
NCT01167166 2017-06-26
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
Traws Pharma, Inc.
Phase 1/2 Completed